2/13/14: New Antiretroviral Agents

Description

Presented by Kirsten Balano, PharmD.

Downloads and Links

    Download

    • Slides (479KB PDF File):  download
    • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study (344KB PDF file):  download
    • Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study (162KB PDF file):  download
    • Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009–2012 (386KB PDF file):  download
    • Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study (396KB PDF file):  download
    • ADAP Formulary for California, October 2013, (113KB PDF file):  download
    • ADAP Formulary for Arizona, January 2014 (86KB PDF file):  download

    Link